230 studies found
In total 153 arrays were analyzed with 6 technical replicates (147 biological samples). CD34+ stem cells, CD4+ T-cells, resting CD14+ monocytes, stimulated monocytes and macrophages were analyzed, all from patient with severe coronary atherosclerosis or controls that had no coronary atherosclerosis as determined angiographically, and which were carefully matched for age and gender.
Biopsies from one of four anatomic locations, from healthy controls and treated (with non-biologic standard of care) or untreated CD patients.
Peripheral blood samples were obtained at week 0 and week 4 of tocilizumab treatment and global gene expression profiling identified markers of responder status.
8 Rheurmatoid arthritis patients have been compared just before and after Leukocytapheresis treatment (overall 16 samples). The Pre-LCAP samples were labeled using Cy5, and the Post-LCAP labeled with Cy3.
mRNA samples were collected from circulating CD4+ and CD8+ T-cells from healthy donors as well as donors with severe and non-severe asthma.
NHEK were treated with IL-19, IL20, IL-22, and IL24, with controls untreated, along with IL1b, IFN gamma, and KGF.
Interim analysis. Study outline is available in Diabetologia (2014) 57:1132–1142.